Stockscreener 앱 받기
9.145
2.30%
-0.215
전일 마감가:
$9.36
열려 있는:
$9.36
하루 거래량:
495.25K
Relative Volume:
0.49
시가총액:
$801.30M
수익:
-
순이익/손실:
$-43.16M
주가수익비율:
-16.63
EPS:
-0.55
순현금흐름:
$-29.31M
1주 성능:
-4.54%
1개월 성능:
+11.66%
6개월 성능:
+18.77%
1년 성능:
+137.53%
1일 변동 폭
$8.80
$9.48
1주일 범위
$8.80
$9.6914
52주 변동 폭
$3.51
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
명칭
Anavex Life Sciences Corporation
전화
844-689-3939
주소
630 5TH AVENUE, NEW YORK
AVXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
9.145 | 801.30M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.09 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.22 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.28 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.20 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.91 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-09-23 | 개시 | BTIG Research | Buy |
| 2020-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-28 | 개시 | Ladenburg Thalmann | Buy |
| 2020-02-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 개시 | Janney | Buy |
| 2018-05-16 | 재개 | Maxim Group | Buy |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-02-07 | 개시 | Noble Financial | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
모두보기
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World
Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com
Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus
Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan
Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Anavex Life Sciences Corporation’s Market Journey: Closing Strong at 9.31, Up 1.09 - DWinneX
Buying Buzz: Anavex Life Sciences Corporation [AVXL] Director Donhauser Peter D.O. purchases 2,835 shares of the company – Knox Daily - knoxdaily.com
AVXL overperforms with a 5.14 increase in share price - uspostnews.com
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - The Manila Times
Harvard-Trained Alzheimer's Pioneer With 35,000-Patient Database Strengthens Anavex's Scientific Team - Stock Titan
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer’s Data ... By GuruFocus - Investing.com Canada
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by LPL Financial LLC - Defense World
Anavex Life Sciences Presents Novel Alzheimer Treatment Research at International Conference in Abu Dhabi - Nasdaq
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East - TradingView
Geode Capital Management LLC Has $20.14 Million Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. (NASDAQ:AVXL) Holdings Raised by Alliancebernstein L.P. - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences LawsuitAVXL - ACCESS Newswire
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Wellington Management Group LLP Makes New $1.70 Million Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Raymond James Financial Inc. Acquires Shares of 15,584 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Prudential Financial Inc. Acquires Shares of 10,160 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Vanguard Group Inc. Sells 59,727 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Corebridge Financial Inc. Trims Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Four-Year Data on New Drug for Early AD Positive - streetwisereports.com
Biotech Company Finds High-Impact Alzheimer's Therapy in Europe - streetwisereports.com
Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World
Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years - Benzinga
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Cuts Cognitive Decline Over 4 Years in Clinical Trial - Stock Titan
Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Anavex Life Sciences Corporation (AVXL)May 13, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class ActionAVXL - ACCESS Newswire
AVXL’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Commonwealth Equity Services LLC Buys 7,285 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at HC Wainwright - Defense World
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Anavex Showcases Breakthrough CNS Therapies: CEO Details Pipeline at Major Healthcare Conference - Stock Titan
Heartland Advisors Inc. Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
19,558 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Acquired by Proficio Capital Partners LLC - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Trading Down 3.2%Here's Why - MarketBeat
AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by Intech Investment Management LLC - The AM Reporter
Anavex Life Sciences Corporation (AVXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anavex Life Sciences Corporation 주식 (AVXL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Donhauser Peter D.O. | Director |
Jun 14 '24 |
Buy |
3.64 |
2,835 |
10,319 |
5,000 |
| Thomas Steffen | Director |
May 15 '24 |
Buy |
4.52 |
5,000 |
22,600 |
5,000 |
0.27%
0.30%
자본화:
|
볼륨(24시간):